Chemosensitivity of Gastric Cancer: Analysis of Key Pathogenic Transcription Factors

Overview

Journal J Gastrointest Oncol

Date 2022 Jul 15

PMID 35837191

Authors

Jianze Weng

Aixiang Wu

Jingwen Ying

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to screen the key pathogenic transcription factors of gastric cancer and analyzed the correlation between the expression of transcription factors and chemotherapy drugs in gastric cancer.

Methods: Gastric cancer RNA sequencing data sets, single nucleotide polymorphism data sets, and corresponding clinical data sets were downloaded from The Cancer Genome Atlas, which is public data. The expression of transcription factors in gastric cancer and normal tissues was analyzed with R software. Pathway enrichment analysis of differentially expressed transcription factors was performed using the Kyoto Encyclopedia of Genes and Genomes database. Univariate Cox analysis was used to explore the correlation between the differential expression of transcription factors and prognosis. The interaction network among differentially expressed transcription factors was constructed using String database. Spearman test was used to explore the correlation between transcription factor mutation and gene expression. The Genomics of Drug Sensitivity in Cancer database was used to examine the relationship between the expression of transcription factors and chemotherapeutic drug sensitivity.

Results: A total of 17 differentially expressed transcription factors were screened. The results indicated that , , , , , and were prognostic risk factors for gastric cancer patients (P<0.05), while and were prognostic protective factors for gastric cancer patients (P<0.05). interacted with , , , , and . gene mutation was positively correlated with the expression level (P<0.05). Based on the median value of , the patients were divided into high expression group and low expression group of . There was no significant difference in IC50 of 5-fluorouracil between the high expression group and the low expression group (P>0.05). The IC50 of paclitaxel in the high expression group was higher than that in the low expression group (P<0.001). The expression of IC50 of cisplatin in the high expression group was higher than that in the low expression group (P<0.05).

Conclusions: was a highly expressed transcription factor in gastric cancer. High expression was associated with the resistance of gastric cancer patients to paclitaxel and cisplatin. Therefore, is a potential therapeutic target for gastric cancer.

Citing Articles

Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1.

Zhang F, Chu M, Liu J, Zhao Q, Zhu Y, Wu X Comb Chem High Throughput Screen. 2023; 27(13):1919-1929.

PMID: 37957853 DOI: 10.2174/0113862073254088231020082912.

mA Methyltransferase KIAA1429 Regulates the Cisplatin Sensitivity of Gastric Cancer Cells via Stabilizing FOXM1 mRNA.

Zhu Z, Zhou Y, Chen Y, Zhou Z, Liu W, Zheng L Cancers (Basel). 2022; 14(20).

PMID: 36291811 PMC: 9600291. DOI: 10.3390/cancers14205025.

References

Hattori Y, Sentani K, Shinmei S, Oo H, Hattori T, Imai T . Clinicopathological significance of RCAN2 production in gastric carcinoma. Histopathology. 2018; 74(3):430-442. DOI: 10.1111/his.13764. View

Wierstra I . FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013; 119:191-419. DOI: 10.1016/B978-0-12-407190-2.00016-2. View

Barger C, Branick C, Chee L, Karpf A . Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer. Cancers (Basel). 2019; 11(2). PMC: 6406812. DOI: 10.3390/cancers11020251. View

Ben Kridis W, Marrekchi G, Mzali R, Daoud J, Khanfir A . Prognostic factors in metastatic gastric carcinoma. Exp Oncol. 2019; 41(2):173-175. DOI: 10.32471/exp-oncology.2312-8852.vol-41-no-2.13283. View

Wang Y, Wen L, Zhao S, Ai Z, Guo J, Liu W . FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer. 2012; 79(2):173-9. DOI: 10.1016/j.lungcan.2012.10.019. View

Khan H, Reale M, Ullah H, Sureda A, Tejada S, Wang Y . Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions. Biotechnol Adv. 2019; 38:107385. DOI: 10.1016/j.biotechadv.2019.04.007. View

Lai J, Li J, Mo X . Clinical Effectiveness of Neoadjuvant Chemotherapy in Gastric Carcinoma and Exploration of Perioperative Imaging Assessment Parameters. Gastroenterol Res Pract. 2021; 2021:5563136. PMC: 8088378. DOI: 10.1155/2021/5563136. View

Yu Y, Zhang Y, Shen N, Zhang R, Lu X . Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med. 2014; 7(4):293-6. DOI: 10.1016/S1995-7645(14)60041-9. View

Lee J, Park Y, Jung M, Lim S . Gene regulatory network analysis with drug sensitivity reveals synergistic effects of combinatory chemotherapy in gastric cancer. Sci Rep. 2020; 10(1):3932. PMC: 7054272. DOI: 10.1038/s41598-020-61016-z. View

10.

Lin J, Wang W, Hu T, Zhu G, Li L, Zhang C . FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy. Cancer Lett. 2019; 469:481-489. DOI: 10.1016/j.canlet.2019.11.014. View

11.

Oliveira L, Oshima C, Soffner P, Silva M, Lins R, de Moraes Malinverni A . THE CANONICAL WNT PATHWAY IN GASTRIC CARCINOMA. Arq Bras Cir Dig. 2019; 32(1):e1414. PMC: 6323632. DOI: 10.1590/0102-672020180001e1414. View

12.

Singh S, Yap W, Arfuso F, Kar S, Wang C, Cai W . Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?. World J Gastroenterol. 2015; 21(43):12261-73. PMC: 4649111. DOI: 10.3748/wjg.v21.i43.12261. View

13.

Jia X, Chen B, Li Z, Huang S, Chen S, Zhou R . Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer. Front Oncol. 2022; 11:799223. PMC: 8790320. DOI: 10.3389/fonc.2021.799223. View

14.

Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y . Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020; 19(1):47. PMC: 7050132. DOI: 10.1186/s12943-020-01171-z. View

15.

Hou J, Tan Y, Su C, Wang T, Gao Z, Song D . Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma p53 signaling pathways. Comput Struct Biotechnol J. 2020; 18:125-136. PMC: 6961071. DOI: 10.1016/j.csbj.2019.12.010. View

16.

Jin X, Jiang M, Wu Z, Fan Y . Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. Curr Med Chem. 2019; 27(14):2322-2334. DOI: 10.2174/0929867326666190204123101. View

17.

Li X, Yao R, Yue L, Qiu W, Qi W, Liu S . FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med. 2014; 18(5):811-23. PMC: 4119387. DOI: 10.1111/jcmm.12216. View

18.

Huang J . Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol Ther. 2020; 220:107720. PMC: 7969395. DOI: 10.1016/j.pharmthera.2020.107720. View

19.

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K . Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol. 2012; 20(3):1035-43. DOI: 10.1245/s10434-012-2680-0. View

20.

Li H, Lu H, Lv M, Wang Q, Sun Y . Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. Oncol Lett. 2018; 15(3):3572-3579. PMC: 5796286. DOI: 10.3892/ol.2018.7739. View